Akebia Therapeutics, Inc. AKBA
At closeNov 6, 2026, 5:22 AM EST
Pre-market · Nov 6, 5:22 AM ET
- YTD
- -73.57%
- 1 year
- -79.93%
- Market cap
- 117.91M
- Revenue (ttm)
- 169.88M
- Profit margin
- -27.07%
- EPS (ttm)
- -0.17
- Shares out
- 218.18M
- Forward P/E
- -7.15
- YTD return
- -73.57%
- 1-year return
- -79.93%
- Volume
- 17.15M
- Avg volume
- 8.04M
- Open
- 0.51
- Previous close
- 0.6947
- Day's range
- 0.4238 – 0.5475
- 52-week range
- 0.4238 – 2.11
- Beta
- 0.73
- Price target
- 5.50 (+1192.6%)
5D -0.2851 (-40.12%)
Key statistics
- Enterprise value
- 468.45M
- PEG ratio
- 0.00
- Price / sales
- 2.39
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -11.00%
- Free cash flow
- 8.98M
- Total cash
- 34.02M
- Total debt
- 103.20M
- Return on equity
- 0.00%
- Short % of float
- 5.35%
- 50-day average
- 1.80
- 200-day average
- 1.45
Analyst view
- Target (low)
- 4.00
- Target (mean)
- 5.50
- Target (high)
- 7.50
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 8, 2025 | Mar 1, 2025 | — | 0.03 | +0.06 | +200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 28, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- akebia.com
News
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3 
12 Health Care Stocks Moving In Thursday's Intraday Session 
What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call 
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates 
Akebia Therapeutics Q3 2026 Earnings Call Transcript 
Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate 
Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights 
Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin 
12 Health Care Stocks Moving In Monday's Intraday Session 
Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat
Your note
Sign in to keep a note on AKBA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS ADRIAN | Director | Stock Award(Grant) | Jun 5, 2024 | 164,800 |
| DAHAN MICHEL | Chief Operating Officer | Sale | May 12, 2024 | 672,092 |
| FRIESON RON | Director | Stock Award(Grant) | Jun 5, 2024 | 73,700 |
| GILMAN STEVEN C | Director | Stock Award(Grant) | Jun 5, 2024 | 117,130 |
| HADAS NICOLE R | Officer | Sale | May 12, 2024 | 651,243 |
| OSTROWSKI ERIK | Chief Financial Officer | Stock Award(Grant) | Jun 27, 2024 | 350,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.97% | 15,197,207 | 28.27M | Sep 29, 2024 |
| Vanguard Group Inc | 4.62% | 10,070,298 | 18.73M | Sep 29, 2024 |
| Alerce Investment Management, L.P. | 2.63% | 5,747,906 | 10.69M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.18% | 4,754,464 | 8.84M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.70% | 3,717,800 | 6.92M | Sep 29, 2024 |
| State Street Corporation | 1.57% | 3,430,527 | 6.38M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.72% | 5,945,188 | 11.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.53% | 5,530,325 | 10.29M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 2,602,859 | 4.84M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.98% | 2,132,609 | 3.97M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.81% | 1,775,159 | 3.30M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 1,083,041 | 2.01M | Oct 30, 2024 |